Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Astellas Pharma Inc
QuantumLeap Healthcare Collaborative
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Dartmouth-Hitchcock Medical Center
Aminex Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Genmab
Exelixis
Dana-Farber Cancer Institute
Seagen Inc.
Japanese Foundation for Cancer Research
Tizona Therapeutics, Inc
Essen Biotech
Memorial Sloan Kettering Cancer Center
Baylor Research Institute
Roswell Park Cancer Institute
Institute of Cancer Research, United Kingdom
IDEAYA Biosciences
Weill Medical College of Cornell University
Emory University
Gilead Sciences
Providence Health & Services
Eli Lilly and Company
National Cancer Centre, Singapore
University of Illinois at Chicago
West German Study Group
UNICANCER
SWOG Cancer Research Network
Vanderbilt-Ingram Cancer Center
Strand Therapeutics Inc.
University of Texas Southwestern Medical Center
Rondo Therapeutics
Medical University of South Carolina
Massachusetts General Hospital
Maastricht University Medical Center
University of Kansas Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Scancell Ltd
UNICANCER
National University Hospital, Singapore
Memorial Sloan Kettering Cancer Center